The details of the poster presentation are as follows:
- Poster #454: Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures
Presenter: Namita Varudkar
Affiliation:University of Central Florida
Session category: Combination immunotherapies
Presentation Dates:Thursday, November 12 ,4:50-5:20 p.m. EST andSaturday, November 14 ,1:00-1:30 p.m. EST
All abstracts are scheduled to be available on the SITC website on
Posters will be on display from
Dutch Translation/Nederlandse vertaling
De details van de posterpresentatie zijn:
- Poster # 454: Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures
Presentator: Namita Varudkar
Aangsloten bij:University of Central Florida
Sessie categorie: Combinatie-immunotherapieën
Presentatiedata: donderdag 12 november, 16.50-17.20 uur EST en zaterdag 14 november, 13:00 -13: 30 uur Est
Alle abstracts zijn naar verwachting beschikbaar op
De posters zijn beschikbaar vanaf maandag 9
Dit persbericht vormt een samenvatting van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd leidend.
Contacts
Kiadis: Tel: +1 (617) 710-7305 m.cimino@kiadis.com | LifeSpring Life Sciences Communication: Tel: +31 538 16 427 lmelens@lifespring.nl Mary Clark, Tel: +44 203 950 9144 kiadis@optimumcomms.com Kiadis_Twitter Kiadis_Twitter |
About Kiadis
Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in
Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis' or, as appropriate, Kiadis' officers' current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
© OMX, source